Original Source(s)
Related Content
Disparities in α 1 -Antitrypsin Deficiency Testing and Treatment in US Adults
by Arianne K. Baldomero, Lisa Smith, Amy Gravely, Vickram Tejwani, Chris H. Wendt
October 15, 2026
FDA grants Temab-A dual Breakthrough status
The designations cover refractory metastatic CRC and previously treated c-Met–expressing NSCLC.
by Mouj Hijazi
October 7, 2026
-
3 min
